Antibiotic Noninferior to Ceftriaxone + Azithromycin for Gonorrhea

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 21, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, April 21, 2025 -- For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin, according to a study published online April 14 in The Lancet.

Jonathan D.C. Ross, M.D., from the Birmingham University Hospitals NHS Foundation Trust in the United Kingdom, and colleagues conducted a phase 3 noninferiority study comparing oral gepotidacin (two 3,000-mg doses administered 10 to 12 hours apart) to 500 mg intramuscular ceftriaxone plus 1 g oral azithromycin for gonorrhea treatment. Eligible participants aged 12 years or older with suspected uncomplicated urogenital gonorrhea, a positive laboratory test for Neisseria gonorrhoeae, or both were randomly assigned to the treatment groups (314 to each group).

The microbiological intention-to-treat population included 406 participants (202 and 204 in the gepotidacin and ceftriaxone plus azithromycin groups, respectively). The researchers found that the results of the primary analysis of microbiological response at test-of-cure (days 4 to 8) demonstrated microbiological success rates of 92.6 and 91.2 percent in the gepotidacin and ceftriaxone plus azithromycin groups, respectively, demonstrating the noninferiority of gepotidacin. At test-of-cure, neither group had bacterial persistence of urogenital N. gonorrhoeae. Higher rates of adverse events and drug-related adverse events were seen in the gepotidacin group, which was mainly due to gastrointestinal adverse events and almost all of which were mild or moderate. Neither group reported treatment-related severe or serious adverse events.

"Gepotidacin is a novel oral antibacterial treatment with the potential to become an alternative option for the treatment of gonococcal infections, supported by an acceptable safety and tolerability profile," the authors write.

Several authors disclosed ties to pharmaceutical companies, including GSK, which manufactures gepotidacin and partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-22 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords